Sensei Biotherapeutics (SNSE), Genetron Holdings (GTH) Stocks Are Notable Winners

Sensei Biotherapeutics Inc (NASDAQ:SNSE) stock soars 31% to $12.73 after the company announced new data from its ongoing Phase 1/2 trial of SNS-301 in patients with advanced squamous cell carcinoma of the head and neck in combination with pembrolizumab.

Sensei Biotherapeutics (SNSE), Genetron Holdings (GTH) Stocks Are Notable Winners

Among efficacy data, in an analysis of anti-tumor activity conducted in 12 patients in Cohort A, 8 of 12 patients achieved stable disease or partial response, including one patient with PD-L1 negative tumor who achieved a tumor reduction of 71% that is still ongoing after 11 months of therapy.

Related:  Senseonic's (SENS) Breakout Alert: Should You Get In?

Genetron Holdings Ltd (NASDAQ:GTH) went18% to $22.87 after the company announced a strategic partnership with JD.com (JD) subsidiary JD Health to create solutions for full-cycle cancer management. The partnership will focus on consumer healthcare and digitization of liver disease management, among other key areas; the first phase of the partnership will focus on liver and lung cancer.

Jack Dawkins

Finance and Tech Contributor